Growth Metrics

Novavax (NVAX) Current Assets (2016 - 2025)

Novavax has reported Current Assets over the past 16 years, most recently at $978.3 million for Q4 2025.

  • Quarterly results put Current Assets at $978.3 million for Q4 2025, down 13.35% from a year ago — trailing twelve months through Dec 2025 was $978.3 million (down 13.35% YoY), and the annual figure for FY2025 was $978.3 million, down 13.35%.
  • Current Assets for Q4 2025 was $978.3 million at Novavax, roughly flat from $974.6 million in the prior quarter.
  • Over the last five years, Current Assets for NVAX hit a ceiling of $2.4 billion in Q2 2021 and a floor of $727.1 million in Q1 2024.
  • Median Current Assets over the past 5 years was $1.1 billion (2023), compared with a mean of $1.5 billion.
  • Biggest five-year swings in Current Assets: surged 780.29% in 2021 and later tumbled 58.63% in 2023.
  • Novavax's Current Assets stood at $2.2 billion in 2021, then fell by 20.96% to $1.7 billion in 2022, then crashed by 32.85% to $1.1 billion in 2023, then decreased by 1.31% to $1.1 billion in 2024, then decreased by 13.35% to $978.3 million in 2025.
  • The last three reported values for Current Assets were $978.3 million (Q4 2025), $974.6 million (Q3 2025), and $919.5 million (Q2 2025) per Business Quant data.